{"id":30760,"date":"2022-09-12T08:00:00","date_gmt":"2022-09-12T06:00:00","guid":{"rendered":"https:\/\/www.transgene.com\/?p=30760"},"modified":"2026-07-09T15:24:41","modified_gmt":"2026-07-09T13:24:41","slug":"les-donnees-de-phase-i-de-tg6002-presentees-a-lesmo-2022-confirment-le-potentiel-des-virus-oncolytiques-invir-io-de-transgene-administres-par-voie-intraveineuse-pour-traiter-les-tumeurs-solides","status":"publish","type":"post","link":"https:\/\/www.transgene.com\/fr\/les-donnees-de-phase-i-de-tg6002-presentees-a-lesmo-2022-confirment-le-potentiel-des-virus-oncolytiques-invir-io-de-transgene-administres-par-voie-intraveineuse-pour-traiter-les-tumeurs-solides\/","title":{"rendered":"Les donn\u00e9es de Phase I de TG6002 pr\u00e9sent\u00e9es \u00e0 l\u2019ESMO\u00a02022 confirment le potentiel des virus oncolytiques Invir.IO\u00ae de Transgene administr\u00e9s par voie intraveineuse pour traiter les tumeurs solides"},"content":{"rendered":"\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n\n\n\n<p class=\"eplus-DVrMbh\"><a href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/Transgene_Communique-Presse-TG6002-ESMO-Poster_FR.pdf\">Les donn\u00e9es de Phase I de TG6002 pr\u00e9sent\u00e9es \u00e0 l\u2019ESMO&nbsp;2022 confirment le potentiel des virus oncolytiques Invir.IO\u2122 de Transgene administr\u00e9s par voie intraveineuse pour traiter les tumeurs solides<\/a><\/p>\n\n\n","protected":false},"excerpt":{"rendered":"<p>&nbsp; &nbsp; Les donn\u00e9es de Phase I de TG6002 pr\u00e9sent\u00e9es \u00e0 l\u2019ESMO&nbsp;2022 confirment le potentiel des virus oncolytiques Invir.IO\u2122 de Transgene administr\u00e9s par voie intraveineuse pour traiter les tumeurs solides<\/p>\n","protected":false},"author":6,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_coblocks_attr":"","_coblocks_dimensions":"","_coblocks_responsive_height":"","_coblocks_accordion_ie_support":"","_uag_custom_page_level_css":"","footnotes":""},"categories":[135,11,56,186],"tags":[],"class_list":["post-30760","post","type-post","status-publish","format-standard","hentry","category-135","category-press-release-fr","category-invirio-fr","category-tg6002","entry"],"uagb_featured_image_src":{"full":false,"thumbnail":false,"medium":false,"medium_large":false,"large":false,"1536x1536":false,"2048x2048":false,"post-thumbnail":false},"uagb_author_info":{"display_name":"Lucie Larguier","author_link":"https:\/\/www.transgene.com\/fr\/author\/lcl\/"},"uagb_comment_info":0,"uagb_excerpt":"&nbsp; &nbsp; Les donn\u00e9es de Phase I de TG6002 pr\u00e9sent\u00e9es \u00e0 l\u2019ESMO&nbsp;2022 confirment le potentiel des virus oncolytiques Invir.IO\u2122 de Transgene administr\u00e9s par voie intraveineuse pour traiter les tumeurs solides","_links":{"self":[{"href":"https:\/\/www.transgene.com\/fr\/wp-json\/wp\/v2\/posts\/30760","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.transgene.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.transgene.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.transgene.com\/fr\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/www.transgene.com\/fr\/wp-json\/wp\/v2\/comments?post=30760"}],"version-history":[{"count":2,"href":"https:\/\/www.transgene.com\/fr\/wp-json\/wp\/v2\/posts\/30760\/revisions"}],"predecessor-version":[{"id":41549,"href":"https:\/\/www.transgene.com\/fr\/wp-json\/wp\/v2\/posts\/30760\/revisions\/41549"}],"wp:attachment":[{"href":"https:\/\/www.transgene.com\/fr\/wp-json\/wp\/v2\/media?parent=30760"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.transgene.com\/fr\/wp-json\/wp\/v2\/categories?post=30760"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.transgene.com\/fr\/wp-json\/wp\/v2\/tags?post=30760"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}